Skip to content
value.today
Advaxis, Inc. logo

Advaxis, Inc.

Total raised
$42 M
8 rounds on record
Latest round
$5 M
Jan 2022
First round on record
Sep 2009
Today
Private
See the company page

Advaxis, Inc. is listed today as Advaxis Inc.: market value, financials and filings are on its company page.

Funding rounds

8 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Advaxis, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2022$5 MNo. 8$2 to $10 million

Advaxis, Inc.: Raise no. 8, Jan 2022

Investors in this round

6 investors had bought by the notice of Feb 11, 2022: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
$380,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
$295,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andres Gutierrez · Executive Officer
  • Igor Gitelman · Executive Officer
  • Kenneth Berlin · Executive Officer, Director
  • David Sidransky · Director
  • James Patton · Director
  • Richard Berman · Director
  • Roni Appel · Director
  • Samir Khleif · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • A.G.P./Alliance Global Partners (CRD 8361) · New York, New YorkSold in IL, NY

Remarks in the notice

  • On fees: “In connection with the transaction, A.G.P./Alliance Global Partners received placement agent fees in the aggregate amount of $295,000.”
  • On the amounts: “This amount reflects a private placement of 1,000,000 shares of the Company's Series D Convertible Redeemable Preferred Stock, par value $0.001, which will be convertible, at a conversion price of $0.25 per share (subject to adjustments).”
  • On the use of proceeds: “The proceeds from the offering will not be used for payments to any of the persons identified as related persons in response to Item 3.”

Signed by Kenneth A. Berlin, President, Chief Executive Officer and Interim CFO. Source: SEC Form D, newest notice filed Feb 11, 2022. Read the notice at the SEC.

equitySEC
Apr 2021$11 MNo. 7$10 to $50 million

Advaxis, Inc.: Raise no. 7, Apr 2021

Investors in this round

2 investors had bought by the notice of Apr 28, 2021: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
$3,000,000
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
$1,104,501
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andres Gutierrez · Executive Officer
  • Kenneth Berlin · Executive Officer, Director
  • David Sidransky · Director
  • Igor Gitelman · Director
  • James Patton · Director
  • Richard Berman · Director
  • Roni Appel · Director
  • Samir Khleif · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • A.G.P./Alliance Global Partners (CRD 8361) · New York, New YorkSold in IL, NY

Remarks in the notice

  • On fees: “In connection with the transaction, A.G.P./Alliance Global Partners received placement agent fees in the aggregate amount of $1,104,501.34, which reflects aggregate fees for private placement and concurrent registered offering.”
  • On the amounts: “Amount reflects purchase price of securities sold in concurrent registered offering which were bundled with private placement warrants to purchase up to 14,005,202 shares of the Company's common stock.”
  • On the use of proceeds: “The proceeds from the offering will not be used for payments to any of the persons identified as related persons in response to Item 3.”

Signed by Kenneth A. Berlin, President, Chief Executive Officer and Interim CFO. Source: SEC Form D, newest notice filed Apr 28, 2021. Read the notice at the SEC.

optionsSEC
May 2012$4 MNo. 6$2 to $10 million

Advaxis, Inc.: Raise no. 6, May 2012

Investors in this round

29 investors had bought by the notice of May 29, 2012: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John L. Rothman · Executive Officer
  • Mark J. Rosenblum · Executive Officer
  • Thomas Moore · Executive Officer, Director
  • James Patton · Director
  • Richard L. Berman · Director
  • Roni A. Appel · Director
  • Thomas L. McKearn · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Advaxis did not receive any cash proceeds in the exchanges. However, certain holders of $4,473,673 of Advaxis' convertible promissory notes surrendered such notes and related warrants in exchange for shares and new warrants.”

Signed by Mark J. Rosenblum, Chief Financial Officer, Senior Vice President and Secretary. Source: SEC Form D, newest notice filed May 29, 2012. Read the notice at the SEC.

equity, optionsSEC
Jan 2012$1 MNo. 5Under $2 million

Advaxis, Inc.: Raise no. 5, Jan 2012

Investors in this round

12 investors had bought by the notice of Feb 24, 2012: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Common Stock issuable upon conversion of notes.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$73,325
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John A. Rothman · Executive Officer
  • Mark J. Rosenblum · Executive Officer
  • Thomas Moore · Executive Officer, Director
  • James Patton · Director
  • Richard A. Berman · Director
  • Roni A. Appel · Director
  • Thomas A. McKearn · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Rodman & Renshaw, LLC (CRD 16415) · New York, New YorkSold in CA, CT, GA, IL, NC, NJ, NY, PA

Remarks in the notice

  • On fees: “Rodman & Renshaw, LLC also received warrants to purchase an aggregate of 575,098 shares of Advaxis, Inc.'s common stock as part of its sales commission.”
  • On the amounts: “Advaxis, Inc. received an aggregate purchase price of $1,047,500.00 in return for issuing to the investors (i) an aggregate of $1,232,352.94 of its convertible promissory notes and (ii) warrants to purchase up to 4,107,842 shares of its common stock.”
  • On the use of proceeds: “No amount of the gross proceeds is anticipated to pay named executive officers, except that the issuer may use up to $200,000 of the gross proceeds or other available funds for payments to its CEO for prior outstanding amounts owed to him.”

Signed by Mark J. Rosenblum, Chief Financial Officer, Senior Vice President and Secretary. Source: SEC Form D, newest notice filed Feb 24, 2012. Read the notice at the SEC.

debt, optionsSEC
Oct 2011$2 MNo. 4Under $2 million

Advaxis, Inc.: Raise no. 4, Oct 2011

Investors in this round

12 investors had bought by the notice of Nov 15, 2011: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Common Stock issuable upon conversion of notes.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$110,425
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John A. Rothman · Executive Officer
  • Mark J. Rosenblum · Executive Officer
  • Thomas Moore · Executive Officer, Director
  • James Patton · Director
  • Richard A. Berman · Director
  • Roni A. Appel · Director
  • Thomas A. McKearn · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Rodman & Renshaw, LLC (CRD 16415) · New York, New YorkSold in CA, CT, GA, IL, NC, NJ, NY, PA

Remarks in the notice

  • On fees: “Rodman & Renshaw, LLC also received warrants to purchase an aggregate of 866,078 shares of Advaxis, Inc.'s common stock as part of its sales commission.”
  • On the amounts: “The investors paid an aggregate purchase price of $1,977,500.00 in return for receiving from Advaxis (i) an aggregate of $2,326,470.59 of Advaxis' convertible promissory notes and (ii) warrants to purchase up to 7,754,899 shares of Advaxis' common stock.”
  • On the use of proceeds: “The notes purchased in this offering by Thomas A. Moore, Advaxis' Chairman and Chief Executive Officer, were paid for in exchange for the cancellation of $400,000.00 of outstanding indebtedness owed by Advaxis to Mr. Moore.”

Signed by Mark J. Rosenblum, Chief Financial Officer, Senior Vice President and Secretary. Source: SEC Form D, newest notice filed Nov 15, 2011. Read the notice at the SEC.

debt, optionsSEC
May 2011$6 MNo. 3$2 to $10 million

Advaxis, Inc.: Raise no. 3, May 2011

Investors in this round

24 investors had bought by the notice of May 27, 2011: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Common Stock issuable upon conversion of notes.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$360,975
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John A. Rothman · Executive Officer
  • Mark J. Rosenblum · Executive Officer
  • Thomas Moore · Director, Executive Officer
  • James Patton · Director
  • Richard A. Berman · Director
  • Roni A. Appel · Director
  • Thomas A. McKearn · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Rodman & Renshaw, LLC (CRD 16415) · Ny, New YorkSold in CA, CO, CT, GA, IL, MA, MN, NC, NJ, NY

Remarks in the notice

  • On fees: “Rodman & Renshaw, LLC also received warrants to purchase an aggregate of 1,887,448 shares of Advaxis, Inc.'s common stock as part of its sales commission.”
  • On the amounts: “Advaxis, Inc. received an aggregate purchase price of $6,016,250.00 in return for issuing to the investors (i) an aggregate of $7,077,936.29 of its convertible promissory notes and (ii) warrants to purchase up to 23,593,122 shares of its common stock.”
  • On the use of proceeds: “No amount of the gross proceeds is anticipated to pay named executive officers, except that the issuer may use up to $200,000 of the gross proceeds or other available funds for payments to the chief executive officer for prior outstanding amounts owed to”

Signed by Mark J. Rosenblum, Chief Financial Officer, Senior Vice President and Secretary. Source: SEC Form D, newest notice filed May 27, 2011. Read the notice at the SEC.

debt, optionsSEC
Jul 2010$8 MNo. 2$2 to $10 million

Advaxis, Inc.: Raise no. 2, Jul 2010

Investors in this round

1 investor had bought by the notice of Jul 30, 2010: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John A. Rothman · Executive Officer
  • Mark J. Rosenblum · Executive Officer
  • Thomas Moore · Director, Executive Officer
  • James Patton · Director
  • Richard A. Berman · Director
  • Roni A. Appel · Director
  • Thomas A. Mckearn · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark J. Rosenblum, Chief Financial Officer, Senior Vice President and Secretary. Source: SEC Form D, newest notice filed Jul 30, 2010. Read the notice at the SEC.

equity, optionsSEC
Sep 2009$5 MNo. 1$2 to $10 million

Advaxis, Inc.: Raise no. 1, Sep 2009

Investors in this round

1 investor had bought by the notice of Oct 5, 2009: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fredrick A. Cobb · Executive Officer
  • John M. Rothman · Executive Officer
  • Thomas A. Moore · Executive Officer, Director
  • James M. Patton · Director
  • Richard M. Berman · Director
  • Roni M. Appel · Director
  • Thomas M. McKearn · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas A. Moore, Chief Executive Officer and Chairman. Source: SEC Form D, newest notice filed Oct 5, 2009. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Advaxis, Inc. had revenue between $1 million and $5 million when it filed its newest notice of a funding round (Feb 2022).

    SEC Form D (revenue range) · Feb 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2022

Products and services#

No products or services of Advaxis, Inc. are on record.

Investors#

No investor of Advaxis, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 8 rounds above had up to 29 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Advaxis, Inc.
NameRoleNamed in
Andres GutierrezExecutive officerFeb 2022
Igor GitelmanExecutive officerFeb 2022
Kenneth BerlinExecutive officerFeb 2022
John L. RothmanExecutive officerMay 2012
Mark J. RosenblumExecutive officerMay 2012
Thomas MooreExecutive officerMay 2012
John A. RothmanExecutive officerFeb 2012
Fredrick A. CobbExecutive officerOct 2009
John M. RothmanExecutive officerOct 2009
Thomas A. MooreExecutive officerOct 2009
David SidranskyDirectorFeb 2022
James PattonDirectorFeb 2022
Kenneth BerlinDirectorFeb 2022
Richard BermanDirectorFeb 2022
Roni AppelDirectorFeb 2022
Samir KhleifDirectorFeb 2022
Igor GitelmanDirectorApr 2021
Richard L. BermanDirectorMay 2012
Roni A. AppelDirectorMay 2012
Thomas L. McKearnDirectorMay 2012
Thomas MooreDirectorMay 2012
Richard A. BermanDirectorFeb 2012
Thomas A. McKearnDirectorFeb 2012
Thomas A. MckearnDirectorJul 2010
James M. PattonDirectorOct 2009
Richard M. BermanDirectorOct 2009
Roni M. AppelDirectorOct 2009
Thomas A. MooreDirectorOct 2009
Thomas M. McKearnDirectorOct 2009

About

American immunotherapy technology development company.